title: Captopril renal scintigraphy--an advance in the detection and treatment of renovascular hypertension.
abstract: Despite the risks associated with renovascular hypertension and the durable benefits of revascularization, the detection of patients with renovascular hypertension and the selection of those who will benefit from interventional therapy remains a challenge. We have previously documented the reliability of captopril renal scintigraphy in predicting angiographically significant renal artery stenosis in patients suspected of having renovascular hypertension. In the present study we report our recent experience with this noninvasive technique in predicting outcome after revascularization. Captopril renal scintigraphy involves the administration of 50 mg of captopril 3 hours after a baseline technitium-99m diethylenetriaminepentaacetic acid renal scan and 1 hour before a repeat captopril renal scintigraphy scan. Nineteen of the last 70 patients with clinically suspected renovascular hypertension undergoing captopril renal scintigraphy had abnormal renal scan outcomes, and 17 had a decrease in flow or function after captopril (positive captopril renal scintigraphy). Eight of these 17 with abnormal findings on captopril renal scintigraphy underwent revascularization, and the hypertension was cured or improved in six of the eight: two of three after surgical bypass grafting and four of five after angioplasty. In the seven surviving patients with abnormal renal scan results but no change with captopril (negative captopril renal scintigraphy), improvement in hypertension after treatment occurred in only one: one of two after nephrectomy, zero of three after bypass surgery, and zero of two after angioplasty (p less than 0.05). We conclude that captopril renal scintigraphy is an accurate predictor of hypertension response to revascularization. Further evaluation of this new noninvasive technique for assessing patients with suspected renovascular hypertension appears warranted.
authors.affiliation: Yale University School of Medicine, Division of Vascular Surgery, New Haven, CT 06510.
authors.forename: G H
authors.initials: GH
authors.lastname: Meier
authors.forename: B
authors.initials: B
authors.lastname: Sumpio
authors.forename: H R
authors.initials: HR
authors.lastname: Black
authors.forename: R J
authors.initials: RJ
authors.lastname: Gusberg
mesh_terms: D000368:Aged; D002216:Captopril; D006801:Humans; D006978:Hypertension, Renovascular / Q000000981:diagnostic imaging* / Q000517:prevention & control; D007668:Kidney / Q000000981:diagnostic imaging*; D008875:Middle Aged; D015609:Organotechnetium Compounds; D004369:Pentetic Acid; D011877:Radionuclide Imaging; D012078:Renal Artery Obstruction / Q000000981:diagnostic imaging* / Q000601:surgery; D016284:Technetium Tc 99m Pentetate
chemical_list: D015609:Organotechnetium Compounds; D004369:Pentetic Acid; D002216:Captopril; D016284:Technetium Tc 99m Pentetate